IR@PKUHSC  > 北京大学第一临床医学院  > 神经内科
学科主题临床医学
Secondary Prevention of Ischemic Stroke in Urban China
Wei, Jade W.1; Wang, Ji-Guang3; Huang, Yining4; Liu, Ming5; Wu, Yangfeng6; Wong, Lawrence K. S.8; Cheng, Yan9; Xu, En10; Yang, Qidong11; Arima, Hisatomi1; Heeley, Emma L.1; Anderson, Craig S.1; ChinaQUEST Investigators
关键词China prevention stroke
刊名STROKE
2010-05-01
DOI10.1161/STROKEAHA.109.571463
41期:5页:967-974
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Clinical Neurology ; Peripheral Vascular Disease
研究领域[WOS]Neurosciences & Neurology ; Cardiovascular System & Cardiology
关键词[WOS]1ST-EVER STROKE ; ATTACK ; INTERVENTION ; GUIDELINES ; ADHERENCE ; VALIDITY ; HISTORY ; CARE
英文摘要

Background and Purpose-We aimed to describe the uptake of proven secondary prevention strategies for ischemic stroke in urban China.

Methods-In a prospective, multicenter, hospital-based registry of 4782 cases of acute ischemic stroke in China during 2006, the use of secondary prevention regimens was evaluated before hospital discharge and 3 and 12 months after stroke. Logistic regression analysis was performed to determine associations between various baseline variables and in-hospital use of antihypertensive, antiplatelet, and lipid-lowering therapies, and to identify variables associated with their continuation at 12 months.

Results-In-hospital initiation of antihypertensive (63%), antiplatelet (81%), and lipid-lowering (31%) therapies was influenced favorably by previous use and comorbid cardiovascular risk factors and unfavorably by stroke severity. Antihypertensive use was well-maintained during follow-up, whereas use of antiplatelet and lipid-lowering therapy decreased (66% and 17%, respectively; P<0.001) by 12 months after stroke, with discontinuation related to patient and physician factors.

Interpretation-There was a high level of uptake of secondary prevention for ischemic stroke in this nationwide sample of hospitalized patients in urban China. However, use of antiplatelet and lipid-lowering therapy declined substantially after discharge, apparently related to misperceptions of subsequent disease risk by both doctors and patients. (Stroke. 2010;41:967-974.)

语种英语
WOS记录号WOS:000277064300023
资助机构Macquarie Bank Foundation ; The George Foundation ; AstraZeneca Pharmaceutical China ; The George Institute for International Health ; Australian postgraduate award
引用统计
被引频次:35[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/66731
专题北京大学第一临床医学院_神经内科
作者单位1.Royal Prince Alfred Hosp, George Inst Int Hlth, Camperdown, NSW 2050, Australia
2.Univ Sydney, Sydney, NSW 2006, Australia
3.Shanghai Jiao Tong Univ, Ctr Epidemiol Studies & Clin Trials, Ruijin Hosp, Sch Med, Shanghai 200030, Peoples R China
4.Peking Univ, Hosp 1, Dept Neurol, Beijing 100871, Peoples R China
5.Tianjin Med Univ, Gen Hosp, Tianjin, Peoples R China
6.Ctr S Univ, Xiangya Hosp, Changsha, Peoples R China
7.Sichuan Univ, W China Hosp, Dept Neurol, Chengdu 610064, Peoples R China
8.Peking Univ, Hlth Sci Ctr, George Inst China, Beijing 100871, Peoples R China
9.Peking Univ, Hlth Sci Ctr, Clin Res Inst, Beijing 100871, Peoples R China
10.Chinese Univ Hong Kong, Prince Wales Hosp, Hong Kong, Hong Kong, Peoples R China
11.Guangzhou Med Coll, Affiliated Hosp 2, Guangzhou, Guangdong, Peoples R China
推荐引用方式
GB/T 7714
Wei, Jade W.,Wang, Ji-Guang,Huang, Yining,et al. Secondary Prevention of Ischemic Stroke in Urban China[J]. STROKE,2010,41(5):967-974.
APA Wei, Jade W..,Wang, Ji-Guang.,Huang, Yining.,Liu, Ming.,Wu, Yangfeng.,...&ChinaQUEST Investigators.(2010).Secondary Prevention of Ischemic Stroke in Urban China.STROKE,41(5),967-974.
MLA Wei, Jade W.,et al."Secondary Prevention of Ischemic Stroke in Urban China".STROKE 41.5(2010):967-974.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Wei, Jade W.]的文章
[Wang, Ji-Guang]的文章
[Huang, Yining]的文章
百度学术
百度学术中相似的文章
[Wei, Jade W.]的文章
[Wang, Ji-Guang]的文章
[Huang, Yining]的文章
必应学术
必应学术中相似的文章
[Wei, Jade W.]的文章
[Wang, Ji-Guang]的文章
[Huang, Yining]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。